Live Feeds
● LIVE Updated 1h ago · 8 sources tracked

Pfizer hikes full-year outlook as newer products grow, taps company veteran as new CFO

Pfizer increased its full-year revenue forecast to between $62 billion and $64 billion following third-quarter earnings that beat expectations. Growth is driven by strong demand for cancer treatments, newly launched products, and the blood thinner Eliquis. Alongside the financial update, the company appointed 20-year veteran Cecile Guegan as Chief Financial Officer this month. The revised profit and sales outlook reflects momentum from recent acquisitions and new product integration into the company's portfolio.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (8)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Pfizer raised its full-year revenue outlook to $62 billion to $64 billion.
  • ✓ Third-quarter earnings exceeded expectations.
  • ✓ The blood thinner Eliquis and cancer drugs contributed to the third-quarter beat.
  • ✓ Cecile Guegan stepped in as CFO this month after 20 years in leadership roles at the company.
🛡️ Source Corroboration: 8 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Pfizer updated its 2026 financial guidance and named Cecile Guegan as its new CFO.

Live updates

  1. Pfizer raises 2026 outlook and appoints Cecile Guegan as CFO

    Pfizer increased its full-year revenue forecast to between $62 billion and $64 billion following third-quarter earnings that beat expectations. Growth is driven by strong demand for cancer treatments, newly launched products, and the blood thinner Eliquis. Alongside the financial update, the company appointed 20-year veteran Cecile Guegan as Chief Financial Officer this month. The revised profit and sales outlook reflects momentum from recent acquisitions and new product integration into the company's portfolio.

    Why it matters

    The company is shifting its revenue base toward new oncology and specialty drugs to sustain growth. These updates follow a period of transition as the firm moves beyond its primary pandemic-era product reliance.

    What is confirmed

    • Pfizer raised its full-year revenue outlook to $62 billion to $64 billion.
    • Third-quarter earnings exceeded expectations.
    • The blood thinner Eliquis and cancer drugs contributed to the third-quarter beat.
    • Cecile Guegan stepped in as CFO this month after 20 years in leadership roles at the company.

    What to watch next

    • Quarterly sales reports for newly acquired cancer drugs
    • Detailed profit margin data for the 2026 fiscal year
    Sources used for this update (9)
    1. CNBC — Pfizer hikes full-year outlook as newer products grow, taps company veteran as new CFO
    2. Quartz — Pfizer beat earnings expectations and raised its full-year sales and profit outlook
    3. Reuters — Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive Q3 beat
    4. Yahoo Finance — Pfizer: Q3 Earnings Snapshot
    5. Bloomberg — Pfizer Raises 2026 Forecast, Extending Big Pharma Windfall
    6. Yahoo Finance — Pfizer increases annual profit forecast amid solid demand for blood thinner drug
    7. WSJ — Pfizer Raises Forecast on Momentum With New Products
    8. www.cnbc.com — Pfizer hikes full-year outlook on new product growth, taps ...
    9. rocketnews.com — Pfizer hikes full-year outlook on new product growth, taps ...
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community